SCHEMBL10126979

SCHEMBL10126979

CS(=O)(=O)c1cc([N+](=O)[O-])ccc1N1CCC(=O)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.63
KMT2A Q03164 2/20 0.63
CYP3A4 P08684 4/20 0.59
CYP2C19 P33261 4/20 0.59
CYP1A2 P05177 3/20 0.59
CYP2C9 P11712 3/20 0.59
NPSR1 Q6W5P4 2/20 0.59
MCOLN3 Q8TDD5 2/20 0.56
CYP2D6 P10635 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
HTT P42858 2/20 0.56
LMNA P02545 3/20 0.51
GAA P10253 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.48
MAPT P10636 1/20 0.47
SLC6A9 P48067 1/20 0.45
SLC6A5 Q9Y345 1/20 0.45
MEN1 O00255 1/20 0.45
HPGD P15428 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17690611 0.86 ALDH1A1 (0.63) ALDH1A1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL16305331 0.86 ALDH1A1 (0.77) ALDH1A1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL10126926 0.80 ALDH1A1 (0.69) ALDH1A1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL29354408 0.78 ALDH1A1 (0.58) ALDH1A1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL10126971 0.78 ALDH1A1 (0.58) ALDH1A1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL25220638 0.77 ALDH1A1 (0.69) ALDH1A1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL3042630 0.77 ALDH1A1 (1.00) ALDH1A1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL328460 0.77 ALDH1A1 (0.65) ALDH1A1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL29744710 0.77 ALDH1A1 (1.00) ALDH1A1KMT2ACYP3A4CYP2C19CYP1A2
SCHEMBL15725834 0.77 ALDH1A1 (0.64) ALDH1A1KMT2ASMN1; SMN2HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885KMT2A 103/4885CYP3A4 3570/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885KMT2A 103/4885CYP3A4 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.